Skip to main content
letter
. 2021 May 27;106(11):2986–2989. doi: 10.3324/haematol.2021.278894

Figure 1.

Figure 1.

Analysis comparing gemtuzumab ozogamicin versus standard treatment in the three subgroups defined by the genotypes with regard to complete remission/complete remission with incomplete hematologic recovery. HR: hazard ratio; 95% CI: 95% confidence interval; CR: complete remission; CRi: complete remission with incomplete hematologic recovery; OR: odds ratio; GO: gemtuzumab ozogamicin.